Matthew Sung PhD

Matthew is a Senior Scientist in the Oncology Research & Development group within Pfizer’s Worldwide Research and Development (WRD) organization. At Pfizer, Matthew leads the pre-clinical development of novel antibody therapeutics. Matthew is an alumnus of the Pfizer WRD Postdoctoral Training Program where he studied mechanisms of ADC resistance. Matthew received his B.S. in Applied Biology from Rose-Hulman Institute of Technology and subsequently completed his Ph. D. in Pharmacology at Weill Cornell Graduate School of Medical Sciences.